<DOC>
	<DOCNO>NCT01411982</DOCNO>
	<brief_summary>This study identify role PACAP ( pituitary adenylate cyclase-activating polypeptide ) deficiency patient nephrotic syndrome . PACAP neuropeptide putative role inhibitor megakaryopoiesis platelet function . Patients nephrotic syndrome show decrease PACAP plasma level , due urinary loss . We hypothesize severe nephrotic syndrome , plasma deficiency PACAP enhance megakaryopoiesis cause blood platelet activation , contribute increase rate thromboembolic disease patient . To test hypothesis , role PACAP deficiency pro-thrombotic state patient nephrotic syndrome study use patient blood urine sample .</brief_summary>
	<brief_title>Role PACAP Nehprotic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Nephrotic Syndrome</mesh_term>
	<mesh_term>Nephrosis</mesh_term>
	<mesh_term>Pituitary Adenylate Cyclase-Activating Polypeptide</mesh_term>
	<criteria>New patient nephrotic syndrome patient relapse nephrotic syndrome Under 16 year old Treatment nephrotic syndrome yet start first sample collection</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>PACAP ( pituitary adenylate cyclase-activating polypeptide )</keyword>
	<keyword>Nephrotic syndrome</keyword>
	<keyword>Thrombosis</keyword>
	<keyword>Platelets</keyword>
</DOC>